SAB Biotherapeutics Inc. (SABS)
3.56
0.01 (0.28%)
At close: Jan 15, 2025, 2:28 PM
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 |
| Revenue | 2.24M | 23.90M | 60.88M | 55.24M | 3.44M |
| Cost of Revenue | 3.75M | 3.29M | 1.65M | n/a | n/a |
| Gross Profit | -1.51M | 20.61M | 59.22M | 55.24M | 3.44M |
| Operating Income | -38.08M | -28.92M | -13.39M | 20.56M | -8.67M |
| Interest Income | 584.97K | 71.07K | 23.11K | 26.13K | 113.13K |
| Pretax Income | -42.19M | -18.72M | -17.14M | 20.12M | -8.99M |
| Net Income | -42.19M | -18.74M | -17.44M | 20.12M | -9.42M |
| Selling & General & Admin | 20.05M | 16.38M | 17.09M | 6.77M | 4.10M |
| Research & Development | 16.52M | 36.44M | 57.18M | 27.91M | 8.02M |
| Other Expenses | n/a | -23.90M | -60.88M | 4.00K | 2.59K |
| Operating Expenses | 36.57M | 28.92M | 13.39M | 34.68M | 12.12M |
| Interest Expense | 315.28K | 301.58K | 294.46K | 469.15K | 428.48K |
| Selling & Marketing Expenses | -3.75M | n/a | n/a | n/a | n/a |
| Cost & Expenses | 40.31M | 28.92M | 13.39M | 34.68M | 12.12M |
| Income Tax | n/a | 25.63K | 299.95K | 473.15K | 431.07K |
| Shares Outstanding (Basic) | 5.52M | 4.35M | 2.73M | 2.54M | 43.47M |
| Shares Outstanding (Diluted) | 5.52M | 4.35M | 2.73M | 2.70M | 43.47M |
| EPS (Basic) | -7.64 | -4.31 | -6.38 | 7.92 | -0.22 |
| EPS (Diluted) | -7.64 | -4.31 | -6.38 | 7.45 | -0.22 |
| EBITDA | -38.13M | -15.12M | -15.20M | 21.14M | -8.23M |
| Depreciation & Amortization | 3.75M | 3.29M | 1.65M | 548.18K | 323.41K |